Loading
Thyroid Disorders and Treatments · Journal article
International Journal of Medical & Pharmaceutical Sciences · July 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a narrative review of a single 2021 in vitro study demonstrating successful CRISPR-Cas9 integration of a reconstructed ancestral uricase gene into the AAVS1 safe harbor locus in human HEK293 cells, with confirmed protein expression, peroxisomal localization, and enzymatic activity on exogenous uric acid substrates. The work is conceptually novel and biochemically sound at the cell level, but remains a proof-of-concept without animal models, hepatocyte systems, biodistribution data, immunogenicity assessment in vivo, or any human clinical validation.
In vitro proof-of-concept; single-arm, uncontrolled HEK293 cell transfection study. HEK293 human embryonic kidney cells in culture; no animal subjects or clinical populations.. Intervention: CRISPR-Cas9-mediated integration of reconstructed ancestral uricase gene (AncUOX) into AAVS1 safe harbor locus, with peroxisomal targeting signal (S-K-L).. Compared with: Non-transduced HEK293 cells (negative control for uricase activity assays).. Not stated..
AncUOX was successfully integrated into AAVS1 locus under both gRNA1 and gRNA2 conditions with sequence verification by Sanger sequencing. Western blot confirmed AncUOX protein expression at ~35 kDa in RFP-positive cells. Immunofluorescent co-staining showed robust colocalization of AncUOX with peroxisomal marker PMP70.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This finding is preclinical and does not directly inform clinical practice. Substantial work—including optimization in primary hepatocytes, animal efficacy and safety studies, off-target assessment, and immune tolerance evaluation—is required before any consideration of human trials.
First-in-human cell culture demonstration of CRISPR-mediated uricase gene restoration with functional enzyme activity, but lacking animal models, toxicology data, or any human in vivo evidence needed for clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
This finding is preclinical and does not directly inform clinical practice. Substantial work—including optimization in primary hepatocytes, animal efficacy and safety studies, off-target assessment, and immune tolerance evaluation—is required before any consideration of human trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background and Rationale: Hyperuricemia—defined as serum uric acid levels exceeding 6 mg/dL in women and 7 mg/dL in men—is a globally prevalent metabolic disorder arising from the evolutionary silencing of the uricase gene in the primate lineage approximately 20 million years ago. This pseudogenization, caused by parallel nonsense mutations introducing premature stop codons, rendered humans and other great apes incapable of degrading uric acid beyond the monosodium urate stage. As a consequence, serum uric acid concentrations in humans (3–7 mg/dL) are substantially higher than in most other mammals (1–2 mg/dL) that retain a functional uricase enzyme. Clinically, elevated uric acid precipitates gout, urate nephropathy, hypertension, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD), representing a significant and growing burden on global health systems. Current pharmacological options, including xanthine oxidoreductase inhibitors (allopurinol, febuxostat) and recombinant uricase preparations (pegloticase/KRYSTEXXA), are limited by incomplete efficacy, high immunogenicity, and serious adverse events. While up to 40% of patients receiving pegloticase produce neutralizing antibodies, about 40% of patients treated with allopurinol do not reach therapeutic urate concentrations. These drawbacks have motivated the search for durable, genome-based solutions. Scope of This Review: This review examines CRISPR-Cas9 homology-directed repair (HDR) as a strategy to genomically integrate a reconstructed ancestral uricase gene (AncUOX) into the human AAVS1 safe harbor locus in HEK293 cells, focusing on the foundational study by Balico and Gaucher (2021). The AncUOX construct encodes a functionally active uricase retaining a peroxisomal targeting signal (S-K-L), ensuring organelle-specific compartmentalization. Two independent guide RNA sequences (gRNA1 and gRNA2) targeting the AAVS1 locus upstream of exon 2 were used by the original investigators in combination with a donor plasmid carrying 800-bp flanking homology arms, a splice acceptor sequence, RFP reporter, and AncUOX separated by T2A self-cleaving peptide sequences. A co-transfected Ad4E4orf6 protein facilitated NHEJ inhibition to promote HDR efficiency. Sanger sequencing, Western blot, immunofluorescence colocalization, and genomic PCR using junction-spanning primers all verified successful integration. Key Findings: AncUOX was precisely and sequence-verifiedly integrated into the AAVS1 locus under both gRNA1 and gRNA2 conditions. Western blot analysis confirmed AncUOX protein expression at the expected molecular weight (~35 kDa) exclusively in RFP-positive (successfully transduced) cells. Immunofluorescent co-staining with the peroxisomal membrane marker PMP70 demonstrated robust colocalization of AncUOX with peroxisomes. Importantly, spectrophotometric uricase activity assays showed that engineered cells effectively oxidized exogenous uric acid at concentrations representing normouricemia (100 μM), moderate hyperuricemia (200–400 μM), and severe hyperuricemia (600 μM, ~10 mg/dL), with statistically significant reduction relative to non-transduced controls (p < 0.05; p < 0.01). Conclusions: The work reviewed here represents the first successful genomic re-engineering of the primate uricase pseudogene in human cells, demonstrating that CRISPR-Cas9-mediated AncUOX integration confers measurable and sustained uricase enzymatic activity. The peroxisomal localization of AncUOX is anticipated to minimize immunogenicity while ensuring catalytic co-detoxification of hydrogen peroxide by-product via co-localized catalase. These results provide an evidence-based foundation for gene therapy strategies aimed at gout, chronic hyperuricemia, and related cardiometabolic disorders. This review argues that future translational studies using hepatocyte-specific delivery systems and organoid models are warranted to advance this approach toward clinical application.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.